Table 4.
Studies comparing survival outcomes between races for women with TNBC
| Study | Study population | Period diagnosed | Median age in years (range)a | Patient (n)a | TNBC or Basal-like (n) | Median F/u in years (range)a | Outcome |
|---|---|---|---|---|---|---|---|
| Lund et al. [21] | 3 counties in metropolitan Atlanta, GA (multi-center population-based, case control study) | May 1990–Dec 1992 | 20–54 | 476 | 135 AA: 56 CA: 79 |
11.4 | HR for OS 2.0 (95 % CI 1.0–3.7) for AA (adjusted for age, stage, grade, poverty index, treatment and treatment delay) |
| O'Brien et al. [29] | 24 counties of eastern and central North Carolina (multi-center, population-based, case control study), enriched for AA and age < 50 years | 1993–2001 | 20–74 | 1,149 | 197 AA: 117 CA: 80 |
9 (0.2–13.7) | HR for breast cancer specific survival 1.3 (95 % CI 0.8–2.3) for AA (adjusted for age, date and stage of diagnosis) |
| Sparano et al. [30] | Participants in a randomized adjuvant chemotherapy trial E1199 | Oct 1999–Jan 2002b | 51 (19–84) | 4, 817 | 886 AA:129 Non-AA: 757 |
7.9 (0–9.9)c | HR for breast cancer specific survival 0.81 (95 % CI 0.51–1.28, p = 0.37) for AA |
| Bauer et al. [22] | A population-based registry covering the state of California | Jan 1999–Dec 2003 | TNBC median 54, other breast cancer types median 60 | 51,074 | 6,370 AA: 636 CA: 3959 |
N/A | 5 yr survival: AA 14 % stage III/IV, CA 36 % stage III/IV, Hispanic 37 % stage III/IV |
| Dawood et al. [28] | Prospective cohort study of database patients at MD Anderson Cancer Center | 1996–2005 | AA: 47 (22–75) Other: 48 (25–78) | 471 | 471 AA: 100 Other: 371 |
2 (0.02–9.75) | HR for DFS 1.08 (95 % CI 0.69–1.68) for CA. HR for OS 1.08 (95 % CI 0.69–1.68, p = 0.735) for CA |
| Sachdev [24] | Retrospective cohort study of patients presenting to the University of Tennessee Cancer Institute | Sep 2003–Dec 2008 | 51 (26–82) | 124 | 124 AA: 88 CA: 36 |
1.91 (0.08–10.3) | HR for DFS 0.62, p = 0.29 for CA, HR for breast cancer specific survival 0.36, p = 0.18 for CA |
| Pacheco et al. (current study) | Retrospective cohort study of patients presenting to the Washington University Saint Louis Breast Oncology Clinic | Jan 1st 2006–Dec 16th 2010 | 53 (23–98) | 490 | 490 AA: 146 CA: 344 |
2.26 (0.01–16.2) | HR for DFS 0.91 (CI 0.62–1.35) p = 0.64 for AA, HR for OS 1.19 (CI 0.80–1.78) p = 0.39 for AA (adjusted for age and stage) |
a
Values represent those for all breast cancer subtypes combined
b
Enrolled during this time period for adjuvant therapy, not diagnosed during this time period
c
Median follow-up for surviving patients